SG11202002422WA - Novel phenylpyridine derivative and pharmaceutical composition comprising the same - Google Patents
Novel phenylpyridine derivative and pharmaceutical composition comprising the sameInfo
- Publication number
- SG11202002422WA SG11202002422WA SG11202002422WA SG11202002422WA SG11202002422WA SG 11202002422W A SG11202002422W A SG 11202002422WA SG 11202002422W A SG11202002422W A SG 11202002422WA SG 11202002422W A SG11202002422W A SG 11202002422WA SG 11202002422W A SG11202002422W A SG 11202002422WA
- Authority
- SG
- Singapore
- Prior art keywords
- same
- pharmaceutical composition
- phenylpyridine derivative
- novel phenylpyridine
- novel
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 150000005359 phenylpyridines Chemical class 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020170131349A KR102613433B1 (ko) | 2017-10-11 | 2017-10-11 | 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물 |
PCT/KR2018/011913 WO2019074275A1 (ko) | 2017-10-11 | 2018-10-11 | 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202002422WA true SG11202002422WA (en) | 2020-04-29 |
Family
ID=66101569
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202002422WA SG11202002422WA (en) | 2017-10-11 | 2018-10-11 | Novel phenylpyridine derivative and pharmaceutical composition comprising the same |
Country Status (23)
Country | Link |
---|---|
US (1) | US11149019B2 (es) |
EP (1) | EP3696176B1 (es) |
JP (1) | JP6876873B2 (es) |
KR (2) | KR102613433B1 (es) |
CN (1) | CN111212833B (es) |
AU (1) | AU2018349293B2 (es) |
BR (1) | BR112020007177A2 (es) |
CA (1) | CA3076667C (es) |
CL (1) | CL2020000940A1 (es) |
CO (1) | CO2020004319A2 (es) |
DO (1) | DOP2020000077A (es) |
EC (1) | ECSP20021379A (es) |
ES (1) | ES2915583T3 (es) |
MA (1) | MA50368A (es) |
MX (1) | MX2020003616A (es) |
MY (1) | MY194695A (es) |
NZ (1) | NZ763263A (es) |
PH (1) | PH12020550252A1 (es) |
RU (1) | RU2748945C1 (es) |
SA (1) | SA520411726B1 (es) |
SG (1) | SG11202002422WA (es) |
TN (1) | TN2020000050A1 (es) |
WO (1) | WO2019074275A1 (es) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
MA50356A (fr) | 2017-10-11 | 2021-04-21 | Hoffmann La Roche | Composés bicycliques destinés à être utilisés en tant qu'inhibiteurs de la kinase rip1 |
WO2021172922A1 (ko) * | 2020-02-26 | 2021-09-02 | 주식회사 대웅제약 | 헤테로사이클릭아민 유도체의 제조 방법 |
KR102531088B1 (ko) * | 2020-02-26 | 2023-05-10 | 주식회사 대웅제약 | 헤테로사이클릭아민 유도체의 제조 방법 |
Family Cites Families (24)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002050071A1 (en) | 2000-12-21 | 2002-06-27 | Bristol-Myers Squibb Company | Thiazolyl inhibitors of tec family tyrosine kinases |
EP1697508A2 (en) * | 2003-12-05 | 2006-09-06 | Vertex Pharmaceuticals, Inc. | Crystal structure of interleukin-2 tyrosine kinase (itk) and binding pockets thereof |
WO2005066335A1 (en) | 2003-12-30 | 2005-07-21 | Boehringer Ingelheim Pharmaceuticals, Inc. | Crystal structure of the interleukin-2-inducible cell kinase (itk) kinase domain |
TW200738680A (en) | 2005-08-04 | 2007-10-16 | Hoffmann La Roche | Phenylpyridine derivatives, their manufacture and use as pharmaceutical agents |
TW200811134A (en) * | 2006-07-12 | 2008-03-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
AR063706A1 (es) | 2006-09-11 | 2009-02-11 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
CN102887900B (zh) | 2006-09-22 | 2015-04-29 | 药品循环公司 | 布鲁顿酪氨酸激酶的抑制剂 |
WO2008154026A1 (en) | 2007-06-11 | 2008-12-18 | Miikana Therapeutics, Inc. | Substituted pyrazole compounds |
CL2008002793A1 (es) * | 2007-09-20 | 2009-09-04 | Cgi Pharmaceuticals Inc | Compuestos derivados de amidas sustituidas, inhibidores de la actividad de btk; composicion farmaceutica que los comprende; utiles en el tratamiento del cancer, trastornos oseos, enfermedades autoinmunes, entre otras |
EP3311818A3 (en) * | 2008-07-16 | 2018-07-18 | Pharmacyclics, LLC | Inhibitors of bruton's tyrosine kinase for the treatment of solid tumors |
US8299077B2 (en) | 2009-03-02 | 2012-10-30 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
CN102458402B (zh) | 2009-06-12 | 2013-10-02 | 百时美施贵宝公司 | 用作激酶调节剂的烟酰胺化合物 |
SG186378A1 (en) * | 2010-06-23 | 2013-01-30 | Hanmi Science Co Ltd | Novel fused pyrimidine derivatives for inhibition of tyrosine kinase activity |
EP2588471A1 (en) * | 2010-06-30 | 2013-05-08 | Amgen Inc. | Heterocyclic compounds and their use as inhibitors of pi3k activity |
WO2012035055A1 (en) * | 2010-09-17 | 2012-03-22 | Glaxo Group Limited | Novel compounds |
EP2441755A1 (en) | 2010-09-30 | 2012-04-18 | Almirall, S.A. | Pyridine- and isoquinoline-derivatives as Syk and JAK kinase inhibitors |
UA111756C2 (uk) * | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
WO2014036016A1 (en) | 2012-08-31 | 2014-03-06 | Principia Biopharma Inc. | Benzimidazole derivatives as itk inhibitors |
CN104822663B (zh) * | 2012-10-04 | 2017-03-08 | 犹他大学研究基金会 | 作为酪氨酸受体激酶btk抑制剂的取代的n‑(3‑(嘧啶‑4‑基)苯基)丙烯酰胺类似物 |
EP3035936B1 (en) | 2013-08-23 | 2019-03-13 | NeuPharma, Inc. | Certain chemical entities, compositions, and methods |
BR112016008632A8 (pt) | 2013-10-21 | 2020-03-17 | Merck Patent Gmbh | compostos de heteroarila como inibidores de btk, seus usos, e composição farmacêutica |
WO2015151006A1 (en) * | 2014-03-29 | 2015-10-08 | Lupin Limited | Substituted purine compounds as btk inhibitors |
WO2015157556A1 (en) | 2014-04-09 | 2015-10-15 | Kadmon Corporation, Llc | Treatment of gvhd |
US9717745B2 (en) * | 2015-03-19 | 2017-08-01 | Zhejiang DTRM Biopharma Co. Ltd. | Pharmaceutical compositions and their use for treatment of cancer and autoimmune diseases |
-
2017
- 2017-10-11 KR KR1020170131349A patent/KR102613433B1/ko active IP Right Grant
-
2018
- 2018-10-11 CA CA3076667A patent/CA3076667C/en active Active
- 2018-10-11 BR BR112020007177-3A patent/BR112020007177A2/pt unknown
- 2018-10-11 SG SG11202002422WA patent/SG11202002422WA/en unknown
- 2018-10-11 MY MYPI2020001499A patent/MY194695A/en unknown
- 2018-10-11 WO PCT/KR2018/011913 patent/WO2019074275A1/ko unknown
- 2018-10-11 AU AU2018349293A patent/AU2018349293B2/en active Active
- 2018-10-11 MX MX2020003616A patent/MX2020003616A/es unknown
- 2018-10-11 US US16/650,441 patent/US11149019B2/en active Active
- 2018-10-11 RU RU2020115083A patent/RU2748945C1/ru active
- 2018-10-11 TN TNP/2020/000050A patent/TN2020000050A1/en unknown
- 2018-10-11 MA MA050368A patent/MA50368A/fr unknown
- 2018-10-11 EP EP18865651.6A patent/EP3696176B1/en active Active
- 2018-10-11 CN CN201880066324.1A patent/CN111212833B/zh active Active
- 2018-10-11 NZ NZ763263A patent/NZ763263A/en unknown
- 2018-10-11 ES ES18865651T patent/ES2915583T3/es active Active
- 2018-10-11 JP JP2020519093A patent/JP6876873B2/ja active Active
-
2020
- 2020-04-07 CL CL2020000940A patent/CL2020000940A1/es unknown
- 2020-04-07 EC ECSENADI202021379A patent/ECSP20021379A/es unknown
- 2020-04-07 SA SA520411726A patent/SA520411726B1/ar unknown
- 2020-04-08 CO CONC2020/0004319A patent/CO2020004319A2/es unknown
- 2020-04-09 PH PH12020550252A patent/PH12020550252A1/en unknown
- 2020-05-06 DO DO2020000077A patent/DOP2020000077A/es unknown
-
2022
- 2022-05-04 KR KR1020220055598A patent/KR20220066012A/ko not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
BR112020007177A2 (pt) | 2020-09-24 |
KR102613433B1 (ko) | 2023-12-13 |
ECSP20021379A (es) | 2020-05-29 |
JP2020536093A (ja) | 2020-12-10 |
CL2020000940A1 (es) | 2020-09-04 |
RU2748945C1 (ru) | 2021-06-02 |
CA3076667A1 (en) | 2019-04-18 |
MY194695A (en) | 2022-12-15 |
ES2915583T3 (es) | 2022-06-23 |
MA50368A (fr) | 2021-03-17 |
US20200223821A1 (en) | 2020-07-16 |
NZ763263A (en) | 2023-02-24 |
AU2018349293A1 (en) | 2020-04-23 |
CO2020004319A2 (es) | 2020-04-24 |
AU2018349293B2 (en) | 2020-10-08 |
EP3696176B1 (en) | 2022-05-04 |
SA520411726B1 (ar) | 2022-06-27 |
DOP2020000077A (es) | 2020-08-15 |
TN2020000050A1 (en) | 2021-10-04 |
KR20190040773A (ko) | 2019-04-19 |
MX2020003616A (es) | 2020-07-28 |
EP3696176A4 (en) | 2021-03-17 |
US11149019B2 (en) | 2021-10-19 |
CN111212833A (zh) | 2020-05-29 |
JP6876873B2 (ja) | 2021-05-26 |
PH12020550252A1 (en) | 2021-02-22 |
CA3076667C (en) | 2022-06-21 |
KR20220066012A (ko) | 2022-05-23 |
EP3696176A1 (en) | 2020-08-19 |
CN111212833B (zh) | 2022-09-06 |
WO2019074275A1 (ko) | 2019-04-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL291291A (en) | A glucagon derivative and a preparation containing its long-term active conjugate | |
HRP20182066T1 (hr) | Novi derivati 4-metoksi pirola ili njihove soli i farmaceutski pripravak koji ih sadrži | |
HK1259145A1 (zh) | 3-脫氧衍生物及其藥物組合物 | |
EP3364951A4 (en) | NICOTINE COMPOSITION FOR VAPOTING DEVICES AND VAPOTING DEVICES USING THE SAME | |
EP3569671A4 (en) | METHYLMENTHOLDER DERIVATIVE AND COMPOSITION THEREOF TO EXERCISE A COOLING EFFECT | |
EP3353213A4 (en) | NOVEL ANTI-MESOTHELIN ANTIBODY AND COMPOSITION COMPRISING SAME | |
EP3675863A4 (en) | PHARMACEUTICAL COMPOSITION CONSISTING OF SEPIAPTERIN AND ITS USES | |
IL269061A (en) | A pharmaceutical preparation containing Selexifag | |
PT3580208T (pt) | Derivados de 2-(3-(1h-benzo[d]imidazol-1-il)propil)piperidin-3-ol e compostos relacionados como inibidores de prs para tratamento de, por exemplo, cancro | |
EP3434285A4 (en) | PHARMACEUTICAL COMPOSITION AND USES THEREOF | |
SG11202008543RA (en) | Pyrrolidineamide derivatives and uses thereof | |
PL3658122T3 (pl) | Kompozycja farmaceutyczna zawierająca sakubitryl i walsartan | |
SG11202002422WA (en) | Novel phenylpyridine derivative and pharmaceutical composition comprising the same | |
EP3448839A4 (en) | CHINAZOLINE DERIVATIVE OR ITS SALT AND PHARMACEUTICAL COMPOSITION THEREWITH | |
SG11202002224XA (en) | Composition and uses thereof | |
IL257621B (en) | A catechol derivative and a pharmaceutical preparation that includes it | |
HK1244275A1 (zh) | 咪唑並嘧啶和咪唑並三嗪衍生物和包含其的藥物組合物 | |
EP3269709A4 (en) | N-phenyl-n'-phenoxycarbonyl-phenylsulfonhydrazide derivative and pharmaceutical composition comprising same | |
ZA202000959B (en) | Adamantylmethylamine derivative and use thereof as pharmaceutical | |
EP3718543A4 (en) | PHARMACEUTICAL COMPOSITION AND ITS USE | |
EP3452078A4 (en) | ISOTOPICALLY MODIFIED COMPOSITION AND THEIR THERAPEUTIC USE | |
HK1253369A1 (zh) | 亮氨酸衍生物、包含其的組合物及其用途 | |
GB201805951D0 (en) | Pharmaceutical composition and method for manufacturing the same | |
EP3653626A4 (en) | NEW 1H-PYRAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION WITH IT | |
GB201713920D0 (en) | Pharmaceutical compositions and uses thereof |